Compare ADMA Biologics Inc (ADMA) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Raytheon Technologies Corp — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Raytheon Technologies Corp trades at $194.82 (market cap $270.48B). The key difference: Raytheon Technologies Corp is far larger — about 127× ADMA Biologics Inc's market cap, and Raytheon Technologies Corp pays a 1.45% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | RTX | |
|---|---|---|
Market Cap | $2.13B | $270.48B |
Sector | Health | Industrials |
52-Week High | $20.38 | $212.16 |
52-Week Low | $7.60 | $144.91 |
Enterprise Value | $2.20B | $302.60B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
RTX trades at $201.37, up 1.06% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a $515 million Navy contract for SPY-6 radars highlight operational momentum. Revenue grew to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock is near its consensus price target of $213, with no sell ratings among 26 analysts.
The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation multiples and geopolitical dependencies. Upside potential exists if the company maintains its earnings beat streak and capitalizes on increased defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
